Last reviewed · How we verify
Marketed enteric-coated naproxen formulation — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Marketed enteric-coated naproxen formulation (Marketed enteric-coated naproxen formulation) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Marketed enteric-coated naproxen formulation TARGET | Marketed enteric-coated naproxen formulation | AstraZeneca | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Marketed enteric-coated naproxen formulation CI watch — RSS
- Marketed enteric-coated naproxen formulation CI watch — Atom
- Marketed enteric-coated naproxen formulation CI watch — JSON
- Marketed enteric-coated naproxen formulation alone — RSS
Cite this brief
Drug Landscape (2026). Marketed enteric-coated naproxen formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/marketed-enteric-coated-naproxen-formulation. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab